Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have brought great clinical benefit to patients with EGFR-sensitive mutations. With the deepening of clinical and basic research, EGFR-TKIs have received more and more attention. In this review, we summarize the latest research development about EGFR-targeted drugs in 2016.
人表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs）给EGFR基因敏感突变患者带来巨大的临床获益。随着临床和基础研究的不断深入，EGFR-TKI已经越来越受到关注。本综述旨在将2016年EGFR-TKI药物研究进展进行概述。.
MeSH terms
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / enzymology
-
Carcinoma, Non-Small-Cell Lung / genetics*
-
Drug Resistance, Neoplasm / drug effects
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics*
-
ErbB Receptors / metabolism
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / enzymology
-
Lung Neoplasms / genetics*
-
Molecular Targeted Therapy / methods*
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use
Substances
-
Protein Kinase Inhibitors
-
ErbB Receptors